Puma Biotechnology Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) 10880 Wilshire Boulevard, Suite 1700, Los Angeles, CA 90024(Address of principal executive offices) (Zip code) (424) 248-6500(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b) of the Exchange Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90 days.Yes☒No☐. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or anemerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company”in Rule 12b-2 of the Exchange Act. Largeacceleratedfiler☐Non-accelerated filer☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒. Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.50,899,456shares of CommonStock, par value $0.0001 per share, were outstanding as ofMay 4, 2026. PUMA BIOTECHNOLOGY, INC. - INDEX - PART I–FINANCIAL INFORMATION:1Item1.Financial Statements (Unaudited):1Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20251Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 20252Condensed Consolidated Statements of Comprehensive (Loss)Income for the Three Months Ended March 31, 2026 and20253Condensed Consolidated Statements of Stockholders’Equityforthe Three Months Ended March 31, 2026and 20254Condensed Consolidated Statements of Cash Flows for the ThreeMonths Ended March 31, 2026and 20255Notes to the Unaudited Condensed Consolidated Financial Statements6Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item3.Quantitative and Qualitative Disclosures About Market Risk29Item4.Controls and Procedures29PART II–OTHER INFORMATION:30Item1.Legal Proceedings30Item 1A.Risk Factors32Item2.Unregistered Sales of Equity Securities and Use of Proceeds32Item3.Defaults Upon Senior Securities33Item4.Mine Safety Disclosures33Item5.Other Information33Item6.Exhibits33Signatures34 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, (this “Quarterly Report”), contains forward-looking statements within the meaning ofSection21E of the Securities Exchange Act of 1934, as amended(the “Exchange Act”). Any statements about our expectations, beliefs, plans,objectives, assumptions, future events or performance are not historical facts and may be forward looking. These forward-looking statementsinclude, but are not limited to, statements about: •the commercialization of NERLYNX®(neratinib) tablets (“NERLYNX”);•the development of our drug candidates, including when we expect to undertake, initiate and complete clinical trials of our drugcandidates;•the anticipated timing of regulatory filings;•the regulatory approval of our drug candidates;•our use of clinical research organizations (“CRO”) and other contractors;•our ability to find collaborative partners for research, development and commercialization of potential products;•efforts of our sub-licensees to obtain regulatory approval and commercialize NERLYNX in areas outside the United States;•our ability to market any of our products;•our expectations regarding our costs and expenses;•our anticipated capital requirements and estimates regarding our needs for additional financing;•our ability to compete against other companies and research institutions;•our ability to secure adequate protection for our intellectual property;•our intention and ability to vigorously defend against any litigation to which we are or may become party;•our ability t